Otsuka Pharmaceutical Development & Commercialization, Inc.
Princeton, NJ, United States
2
Total Recalls
0
Class I Recalls
0
Ongoing Recalls
Recalls by Otsuka Pharmaceutical Development & Commercialization, Inc.
FDA Drug
Class III
Terminated
treatNOW ABILIFY (aripiprazole) / ABILIFY MAINTENA 400-mg (aripiprazole) for extended release injectable suspension. Kit contents 2 packs Abilify Tablets 10 mg (14 day supply) plus 1 Abilfy Maintena V
September 17, 2018
Otsuka Pharmaceutical Development & Commercialization, Inc.
4738 kits units
FDA Drug
Class III
Terminated
treatNOW ABILIFY (aripiprazole) and ABILIFY MAINTENA (aripiprazole) 400MG for extended release injectable suspension. Kit Contents: 2 packs ABILIFY Tablets 10mg (14 day supply) plus 1 ABILIFY MAINTENA
September 17, 2018
Otsuka Pharmaceutical Development & Commercialization, Inc.
17325 kits units